At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 130 enrolled
Drug / intervention
CT1812drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
In Brief
A Phase 2 clinical trial evaluating CT1812 for Dementia With Lewy Bodies. Completed, enrolled 130 participants across 34 sites.
Detailed Summary
Multi-center, randomized, double-blind, placebo-controlled, 6- month study in subjects with mild to moderate Dementia with Lewy Bodies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia With Lewy Bodies
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartMay 2022
Primary CompletionNov 2024
TodayJul 2026
First PostedFeb 4, 2022
Enrollment StartMay 19, 2022
Primary CompletionNov 25, 2024
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.4 years ago
Interventions
CT1812drug
Orally administered CT1812